<DOC>
	<DOCNO>NCT01171313</DOCNO>
	<brief_summary>The purpose study assess efficacy safety XP21279/Carbidopa comparison Sinemet well evaluate pharmacokinetics ( PK ) levodopa administration XP21279/Carbidopa Sinemet explore exposure-response relationship subset subject .</brief_summary>
	<brief_title>A Efficacy , Safety Pharmacokinetic Study XP21279 Sinemet® Parkinson 's Disease Subjects</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>1 . Subjects must predictable motor fluctuation wear type , define meeting follow criterion base on/off diary record 3 day Screening Period : Wearingoff least half ( 50 % ) interdose interval first last daily dos average 3 diary day , An average daily `` '' time 2 hour first `` '' day awake time midnight . 2 . Subjects must one follow stable QID 5 time daily regimen least 4 week prior Screening : Sinemet® carbidopalevodopa , total daily dose range 400 mg 1000 mg levodopa 1 . History , sign , symptom suggest diagnosis secondary atypical Parkinsonism . 2 . Subject moderately severely disable dyskinesia great 25 % wake day 3 . Subjects significant neurological symptom account Parkinson 's disease 4 . Subjects take Sinemet® CR , Parcopa® , concomitant COMT inhibitor ( i.e. , entacapone tolcapone ) , Stalevo® , benserazide contain levodopa preparation Madopar® Prolopa® .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>